Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) – Stock analysts at SVB Leerink increased their FY2023 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, September 19th. SVB Leerink analyst M. Foroohar now forecasts that the company will post earnings per share of ($4.90) for the year, up from their previous estimate of ($4.92). SVB Leerink currently has a “Outperform” rating and a $158.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.83) per share.
Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last issued its earnings results on Thursday, August 4th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The company had revenue of $14.00 million during the quarter, compared to analyst estimates of $9.50 million. Intellia Therapeutics had a negative return on equity of 40.23% and a negative net margin of 883.17%. The business’s revenue was up 115.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.01) earnings per share.
Intellia Therapeutics Stock Performance
Shares of NASDAQ NTLA opened at $62.53 on Wednesday. The stock’s fifty day simple moving average is $62.95 and its 200 day simple moving average is $58.02. Intellia Therapeutics has a 52-week low of $37.08 and a 52-week high of $155.63.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Prospera Financial Services Inc acquired a new position in Intellia Therapeutics during the 1st quarter worth $32,000. Newbridge Financial Services Group Inc. lifted its holdings in Intellia Therapeutics by 49.2% during the 1st quarter. Newbridge Financial Services Group Inc. now owns 776 shares of the company’s stock worth $56,000 after buying an additional 256 shares in the last quarter. Herold Advisors Inc. acquired a new position in Intellia Therapeutics during the 1st quarter worth $62,000. Penserra Capital Management LLC acquired a new position in Intellia Therapeutics during the 1st quarter worth $97,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Intellia Therapeutics by 10.2% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company’s stock worth $123,000 after buying an additional 220 shares in the last quarter. 88.18% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
- Get a free copy of the StockNews.com research report on Intellia Therapeutics (NTLA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.